We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Non-Invasive Urine Test Detects Prostate Cancer

By LabMedica International staff writers
Posted on 15 Mar 2018
Print article
Image: The CellDetect platform is the only histochemical solution providing color discrimination between normal, pre-cancer and cancer cells alongside morphological examination (Photo courtesy of Micromedic Technologies).
Image: The CellDetect platform is the only histochemical solution providing color discrimination between normal, pre-cancer and cancer cells alongside morphological examination (Photo courtesy of Micromedic Technologies).
Prostate cancer is the second most common cancer among men worldwide. About one man in nine will be diagnosed with prostate cancer during his lifetime. It is estimated that in the USA for 2018 there will be about 165,000 new cases of prostate cancer and about 29,000 deaths from prostate cancer.

Prostate cancer is initially diagnosed by digital rectal exam and if the doctor finds any abnormalities in the texture, shape or size of the gland, the patient may need further tests. The Prostate-specific antigen (PSA) test is used to analyze a blood sample for a substance that is naturally produced by the prostate gland.

A clinical study carried out by scientists at Kaplan Medical Center (Rehovot, Israel) included 59 urine samples (28 positive prostate cancer patients and 31 healthy subjects) that were collected and examined by a cytopathologist using the CellDetect unique color marker. CellDetect is a new-generation cytopathological staining platform for accurate cancer detection. It offers proprietary diagnostic solutions based on unique combination of color and morphology. The CellDetect efficacy was proven for cervical and bladder cancer in multiple clinical studies and it is estimated that the technology can be implemented for use in additional cancer detection indications.

The team found that of the 59 samples tested, a high rate of 80% of the samples received a definite diagnosis, and accordingly, included in the clinical study results. The results of the positive prostate cancer patients were compared to biopsy results that these patients had undergone prior to the clinical study. The study results demonstrated that Micromedic's product successfully detected prostate cancer cells in urine samples, in a high sensitivity of 91.3% and specificity of 75%.

Guy Lerner, MBA, CEO of Micromedic, said, “We are very pleased with the results from this clinical study, which indicates the potential we see in the CellDetect technology to dramatically improve prostate cancer diagnostics. While prostate cancer is the second most common cancer in men worldwide, the currently available diagnostic testing is known to be unreliable. With these clinical study results, we are confident that our product has the potential to transform prostate cancer diagnostics, offering patients a non-invasive, accurate and reliable test, and one that could improve the healthcare system through considerable cost savings.”

Related Links:
Kaplan Medical Center


Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
One Step HbA1c Measuring System
GREENCARE A1c
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
Xylazine Immunoassay Test
Xylazine ELISA

Print article

Channels

Clinical Chemistry

view channel
Image: Reaching speeds up to 6,000 RPM, this centrifuge forms the basis for a new type of inexpensive, POC biomedical test (Photo courtesy of Duke University)

POC Biomedical Test Spins Water Droplet Using Sound Waves for Cancer Detection

Exosomes, tiny cellular bioparticles carrying a specific set of proteins, lipids, and genetic materials, play a crucial role in cell communication and hold promise for non-invasive diagnostics.... Read more

Molecular Diagnostics

view channel
Image: The study showed the blood-based cancer screening test detects 83% of people with colorectal cancer with specificity of 90% (Photo courtesy of Guardant Health)

Blood Test Shows 83% Accuracy for Detecting Colorectal Cancer

Colorectal cancer is the second biggest cause of cancer deaths among adults in the U.S., with forecasts suggesting 53,010 people might die from it in 2024. While fewer older adults are dying from this... Read more

Hematology

view channel
Image: The Gazelle Hb Variant Test (Photo courtesy of Hemex Health)

First Affordable and Rapid Test for Beta Thalassemia Demonstrates 99% Diagnostic Accuracy

Hemoglobin disorders rank as some of the most prevalent monogenic diseases globally. Among various hemoglobin disorders, beta thalassemia, a hereditary blood disorder, affects about 1.5% of the world's... Read more

Microbiology

view channel
Image: The new platform is designed to perform blood-based diagnoses of nontuberculosis mycobacteria (Photo courtesy of 123RF)

New Blood Test Cuts Diagnosis Time for Nontuberculous Mycobacteria Infections from Months to Hours

Breathing in nontuberculous mycobacteria (NTM) is a common experience for many people. These bacteria are present in water systems, soil, and dust all over the world and usually don't cause any problems.... Read more

Industry

view channel
Image: These new assays are being developed for use on the recently introduced DxI 9000 Immunoassay Analyzer (Photo courtesy of Beckman Coulter)

Beckman Coulter and Fujirebio Expand Partnership on Neurodegenerative Disease Diagnostics

Beckman Coulter Diagnostics (Brea, CA, USA) and Fujirebio Diagnostics (Tokyo, Japan) have expanded their partnership focused on the development, manufacturing and clinical adoption of neurodegenerative... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.